

CAVELIER
ABOGADOS

348

WEB SITE: www.cavelier.com
E-MAIL: cavelier@cavelier.com

EDIFICIO SISKI
CARRERA 4 No. 72 - 35
BOGOTÁ 8, COLOMBIA

TELEFONO: (57) (1) 347-3611
TELEFAX: (57) (1) 211-8650 (57) (1) 547-3170

Señora Jefe de la
DIVISION DE NUEVAS CREACIONES
Superintendencia de Industria y Comercio
E. S. D.

SUPERINDUSTRIA Y COMERCIO
Radicación: 04083750 00000001 Folios: 19
Fecha (MID): 2004-09-06 17:02:28
Trámite: 011 PCT-PATENT 379 FASE NOCI 329 COMPLETOS
Dependencia: 2020 DIVISION DE NUEVAS CREACIONES


Trámite :011
Evento :379
Actuación:329

Referencia : Expediente No. 04083750
Asunto : Solicitud de patente para
"COMPOSICIONES Y METODOS PARA MODULAR
HEMICANALES DE CONEXINA"
Solicitante : WYETH
Fecha de Solicitud : 26 de agosto de 2004

1 Yo, Emilio FERRERO, obrando como apoderado de la sociedad solicitante, en el asunto de la referencia, atentamente presento, junto con este memorial, los documentos a continuación:

- 1.1. Copia completa del Informe de Búsqueda Internacional.
- 1.2. Copia del Informe de Examen Preliminar Internacional junto con la correspondiente traducción al español.
- 1.3. Copia Formato PCT/IB/306 mediante el cual la Oficina Internacional de la WIPO Notifica el Registro de Cambio de solicitante de la compañía ZEALAND PHARMA A/S a la compañía WYETH.

Bogotá, - 6 SET. 2004
Señora Jefe,


EMILIO FERRERO
T.P.A. No. 31.929

 COLO 13885 841 001 8
DLM/DLM/ID-000009/WPC13885

N I T. 860.041.367-3

PATENT COOPERATION TREATY

PCT

349

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 016-2003 WO	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, Item 5 below.	
International application No. PCT/DK 03/ 00056	International filing date (day/month/year) 29/01/2003	(Earliest) Priority Date (day/month/year) 29/01/2002
Applicant ZEALAND PHARMA A/S		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 5 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

- a. With regard to the language, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of the sequence listing:

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

2. ☒ Certain claims were found unsearchable (See Box I).

3. ☐ Unity of invention is lacking (see Box II).

4. With regard to the title,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the abstract,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the drawings to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☒ None of the figures.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/DK 03/00056

350

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K38/08 A61P9/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data, BIOSIS

NO FOREIGN PRIORITY

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/DK 03/00056

351

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K38/08 A61P9/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 02 077017 A (HOLSTEIN-RATHLOU NIELS-HENRIK ;KJOLBYE ANNE LOUISE (DK); LARSEN BJ) 3 October 2002 (2002-10-03) the whole document	1-46
X	WO 01 62775 A (HOLSTEIN RATHLOU NIELS HENRIK ;JOERGENSEN NIKLAS RYE (DK); LARSEN) 30 August 2001 (2001-08-30) the whole document	1-46

☐ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another claim or other special reason (see explanation)
- "O" document relating to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is considered with one or more other such documents, such combination being obvious to a person skilled in the art
- "Z" document member of the same patent family

Date of the actual completion of the international search

12 May 2003

Date of filing of the international search report

26.05.2003

Name and mailing address of the ISA

European Patent Office, P.O. Box 1
NL-2000 HV Rijswijk
Tel. (+31-70) 340 8040, Tx. 31 051 epo nl,
Fax (+31-70) 340 8010

Authorized officer

CAROLINA LAGERLÖF /ELY

INTERNATIONAL SEARCH REPORT

International application No.
PCT/DK 83/00056

352

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-14, 37-46
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/219
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependant claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 218

Continuation of Box I.1

Claims Nos.: 1-14,37-46

Claims 1-14, 37-46 relate to methods of treatment of the human or animal body by surgery or by therapy/diagnostic methods practised on the human or animal body/Rule 39.1.(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds/compositions.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/DK 03/00056

354

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 02077017	A	03-10-2002	AU	3536201 A	03-09-2001
			CA	2385659 A1	30-08-2001
			EP	1226160 A2	31-07-2002
			WO	02077017 A2	03-10-2002

WO 0162775	A	30-08-2001	AU	3536201 A	03-09-2001
			CA	2385659 A1	30-08-2001
			WO	0162775 A2	30-08-2001
			EP	1226160 A2	31-07-2002

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT
(PCT Article 36 and Rule 70)

REC'D 16 MAR 2004

WIPO PCT

Applicant's or agent's file reference 016-2003 WO1, MH/LSD	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/ISA/10)	
International application No. PCT/DK 03/00058	International filing date (day/month/year) 29.01.2003	Priority date (day/month/year) 29.01.2002
International Patent Classification (IPC) or both national classification and IPC A61K38/08		
Applicant ZEALAND PHARMA AS et al.		
1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36. 2. This REPORT consists of a total of 5 sheets, including this cover sheet. ☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 807 of the Administrative Instructions under the PCT). These annexes consist of a total of sheets. EPO - DG 1		
3. This report contains indications relating to the following items: I ☒ Basis of the opinion II ☐ Priority III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability IV ☐ Lack of unity of invention V ☒ Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement VI ☐ Certain documents cited VII ☐ Certain defects in the international application VIII ☐ Certain observations on the international application		
Date of submission of the demand 25.08.2003	Date of completion of this report 12.03.2004	
Name and mailing address of the international preliminary examining authority:  European Patent Office D-60298 Munich Tel. +49 89 2339 - 0 Tlx 523950 epmu d Fax: +49 89 2339 - 4488	Authorized Officer Deck, A Telephone No. +49 89 2339-8432 	

356

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. **PCT/DK 03/00058**

I. Basis of the report

1. With regard to the elements of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

Description, Pages

1-68 as originally filed

Claims, Numbers

1-46 as originally filed

Drawings, Sheets

1/4-14/14 as originally filed

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

357

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. **PCT/DK 03/00056**

6. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)).
(Any replacement sheet containing such amendments must be referred to under Item 1 and annexed to this report.)

6. Additional observations, if necessary:

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application,

☒ claims Nos. 1-14, 30-33, 38-45

because:

☒ the said international application, or the said claims Nos. 1-14, 30-33, 38-45 relate to the following subject matter which does not require an international preliminary examination (specify):

see separate sheet

☐ the description, claims or drawings (indicate particular elements below) or said claims Nos. are so unclear that no meaningful opinion could be formed (specify):

☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.

☐ no international search report has been established for the said claims Nos.

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

☐ the written form has not been furnished or does not comply with the Standard.

☐ the computer readable form has not been furnished or does not comply with the Standard.

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes: Claims	15-29,34,35
	No: Claims	1-14, 30-33, 38-45 (NO)
Inventive step (IS)	Yes: Claims	
	No: Claims	1-45 (NO)
Industrial applicability (IA)	Yes: Claims	15-29,34,35
	No: Claims	see separate sheet

2. Citations and explanations

358

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/DK 03/00056

see separate sheet

359

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/DK03/00056

Concerning section III

Claims 1-14, 30-33, 36-45 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(i) PCT).

Concerning section V

1. The following document is referred to:

D1: WO 01 62775 A (HOLSTEIN RATHLOU NIELS HENRIK ;JOERGENSEN
NIKLAS RYE (DK); LARSEN) 30 August 2001 (2001-08-30)

2. The document D1 from the applicant discloses the use of the antiarrhythmic peptides of the present application for the treatment of the same disorders, see claims 112-161.
Hence the subject-matter of claims 1-14, 30-33, 36-45 is not novel.
3. The screening methods claimed in claims 15-29, 34, 35 are well-known methods in the art. Applying these methods to the peptides of D1 does not need particular inventive skills, hence the subject-matter of claims 15-29, 34 and 35 is not seen as being inventive.
4. For the assessment of the present claims 1-14, 30-33, 36-45 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

360

TRATADO DE COOPERACIÓN DE PATENTES
PCT
INF RME DE EXAMEN PRELIMINAR INTERNACIONAL
(Artículo 36 y Regla 70 del PCT)

Referencia del expediente del agente o solicitante 016-2003 WO1, MH/LSD	PARA ACTUACIONES ADICIONALES	Ver notificación de Transmisión del Reporte de Examen Preliminar (Formato PCT/IPEA416)
Solicitud Internacional No. PCT/DK03/00056	Fecha de presentación Internacional (día/mes/año) 29/01/2003	Fecha de prioridad (día/mes/año) 29/01/2002
Clasificación Internacional de Patentes (IPC) o clasificación nacional e IPC A61K 38/08		
Solicitante ZEALAND PHARMA A/S et al.		

1. Este informe de examen preliminar internacional ha sido preparado por esta Administración encargada del Examen Preliminar Internacional y se envía al solicitante en concordancia con el artículo 36. 2. Este INFORME consta de una total de <u>5</u> hojas, incluyendo la portada ☐ Este informe también se acompaña de ANEXOS, esto es documentos de la descripción, reivindicaciones y/o dibujos que han sido corregidos y que son la base de este informe y/o documentos que contienen rectificaciones realizadas ante esta Administración (Ver Regla 70.16 y Sección 607 de las Instrucciones Administrativas según el PCT) Estos anexos constan de un total de _____ hojas.
3. Este informe contiene indicaciones relativas a los siguientes aspectos: I ☒ Fundamentos del Informe II ☐ Prioridad III ☒ No se establece concepto relativo a la novedad, nivel inventivo y aplicación Industrial IV ☐ Carencia de unidad de la Invención V ☒ Declaración razonada según el artículo 35(2), en relación con la novedad, nivel inventivo o aplicación industrial; citaciones y explicaciones que soportan dicha declaración VI ☐ Ciertos documentos citados VII ☐ Ciertos defectos de la solicitud Internacional VIII ☐ Ciertas observaciones respecto a la solicitud internacional

Fecha de presentación de la demanda 25/08/2003	Fecha de terminación de este reporte 12/03/2004
Nombre y dirección de correo de la autoridad encargada del examen preliminar European Patent Office D-80298 Munich Tel.+49 89 2399-0 Tx: 523656 epmu d Fax: +49 89 2399 - 4485	Funcionario Autorizado Deck, A Teléfono No. +49 89 2399-8432

Formato PCT/IPEA/409 (portada) (julio 1998)

361

I. Base del Informe

1. Respecto a los elementos de la solicitud internacional (Las hojas de reemplazo que han sido entregadas a la Oficina receptora en respuesta a la invitación bajo el Artículo 14 se refieren en este informe como "originalmente presentadas" y no se anejan a este informe ya que ellas no contienen modificaciones (Regla 70.16 y 70.17).

- ☒ La descripción:
páginas 1 - 68, como se presentaron originalmente
- ☒ Las reivindicaciones:
números 1 - 45, como se presentaron originalmente
- ☒ Los dibujos:
páginas 1/14 - 14/14, como se presentaron originalmente

2. Respecto al lenguaje, todos los elementos marcados anteriormente estuvieron disponibles o fueron enviados a la Administración en el lenguaje en que se presentó la solicitud internacional, a menos que se indique otra cosa en este punto.

Estos elementos estuvieron disponibles o fueron enviados a esta Administración en el siguiente lenguaje _____ el cual es:

- ☐ el lenguaje de la traducción enviada para propósitos de la búsqueda internacional (bajo Regla 23.1 (b)).
- ☐ el lenguaje de la publicación de la solicitud internacional (bajo Regla 48.3(b)).
- ☐ el lenguaje de la traducción entregada con propósitos del examen preliminar internacional (bajo Regla 55.2 y/o 55.3).

3. Respecto a cualquier secuencia de nucleótido y/o amino ácidos divulgada en la solicitud internacional, el examen preliminar internacional se llevó a cabo con base en el listado de secuencias:

- ☐ contenido en la solicitud internacional en forma escrita
- ☐ presentado junto con la solicitud internacional en forma legible por computador
- ☐ entregado posteriormente a esta Administración en forma legible por computador
- ☐ La declaración de que el listado de secuencias posteriormente entregado no va más allá de lo divulgado en la solicitud internacional originalmente presentada, ha sido entregada.
- ☐ La declaración de que la información grabada en la forma legible por computador es idéntica al listado de secuencias escrito que se ha entregado.

4. Las modificaciones han dado como resultado la cancelación de:

- ☐ la descripción, páginas _____
- ☐ las reivindicaciones, Nos. _____
- ☐ los dibujos, página _____

362

5. ☐ Este reporte ha sido establecido como si (parte de) las modificaciones no se hubieran realizado, ya que éstas han sido consideradas como una ampliación de lo inicialmente divulgado como se indica en la Casilla Suplementaria (Regla 70.2(c)).

(Cualquier hoja de reemplazo que contenga dichas modificaciones deberá ser referida bajo el punto 1 y anexada a este informe).

6. Observaciones adicionales, en caso de ser necesario:

III. No establecimiento de opinión con respecto a la novedad, nivel inventivo y aplicabilidad Industrial.

1. La pregunta de si la invención reivindicada parece tener novedad, nivel inventivo (que no sea obvia), o que sea aplicable industrialmente no ha sido examinada con respecto a:

- ☐ la solicitud internacional completa
☒ las reivindicaciones Nos. 1 - 14, 30 - 33, 36 - 45,

Porque

- ☒ la solicitud internacional, o las mencionadas reivindicaciones Nos. 1 - 14, 30 - 33, 36 - 45 se relacionan con los siguientes objetos, los cuales no requieren examen preliminar internacional (*especifique*):

ver hoja aparte

- ☐ la descripción, las reivindicaciones o los dibujos (*indique los elementos particulares abajo*) o las mencionadas reivindicaciones Nos. _____ son demasiado confusas que no se puede formar ninguna opinión significativa (*especifique*):

- ☐ la descripción, o las mencionadas reivindicaciones Nos. _____ no están adecuadamente soportadas por la descripción que no se puede formar ninguna opinión significativa.

- ☐ no se ha establecido un reporte de búsqueda para las mencionadas reivindicaciones Nos. _____

2. No se pudo realizar un examen preliminar internacional significativo debido a fallas en el listado de nucleótidos y/o aminoácidos para dar cumplimiento con los estándares del Anexo C de las Instrucciones Administrativas:

- ☐ El formato escrito no ha sido suministrado o no cumple con los estándares.

- ☐ El formato de lectura por computador no ha sido suministrado o no cumple con los estándares.

363

V. Declaración motivada según el Artículo 35(2) en cuanto a la novedad, el nivel inventivo y la aplicación Industrial; citas y explicaciones que apoyan esta declaración.

1. Declaración

Novedad (N)	Reivindicaciones	15 – 29, 34 , 35	SI
	Reivindicaciones	1 – 14, 30 – 33, 36 – 45	NO
Nivel inventivo (NI)	Reivindicaciones		SI
	Reivindicaciones	1 – 45	NO
Aplicación industrial (AI)	Reivindicaciones	15 – 29, 34, 35	SI
	Reivindicaciones	ver hoja aparte	NO

2. Citas y explicaciones

Ver hoja aparte

364

Recuadro Suplementario

(Para ser usado cuando el espacio en alguno de los cuadros anteriores no es suficiente)

Con relación a la sección III

Las reivindicaciones 1 – 14, 30 – 33, 36 – 45 se relacionan con una materia objeto considerada por esta Autoridad como que esta cubierta por las salvedades de la Regla 67.1 (iv) del PCT. En consecuencia, no se va a formular ninguna opinión con respecto a la aplicabilidad industrial de la materia objeto de dichas reivindicaciones (artículo 34(4) (a) (i) del PCT).

Con relación a la sección V

1. Se hace referencia al siguiente documento:

D1: WO 01 63775 A (HOLSTEIN RATHLOU NIELS HENRIK, JOERGENSEN NIKLAS RYE (DK); LARSEN) 30 de agosto de 2001 (2001-08-30)

2. El documento D1 del solicitante revela el uso de los péptidos antiarrítmicos de la presente solicitud para el tratamiento de las mismas enfermedades, ver reivindicaciones 112 a 161.

Por lo tanto la materia objeto de las reivindicaciones 1 – 14, 30 – 33, 36 – 45 no es novedosa.

3. Los métodos de tamizado reivindicados en las reivindicaciones 15 – 29, 34, 35 son métodos bien conocidos en el arte. La aplicación de estos métodos a los péptidos del documento D1 no requiere de aptitudes inventivas particulares, por lo tanto la materia objeto de las reivindicaciones 15 – 29, 34 y 35 no parece ser inventiva.

4. Para la evaluación de las presentes reivindicaciones 1 - 14, 30 – 33, 36 – 45 sobre la pregunta si las mismas tienen aplicabilidad industrial, no hay un criterio unificado

entre los Países Miembros del PCT. La patentabilidad también puede depender de la formulación de las reivindicaciones. La Oficina de Patentes Europea, por ejemplo, no reconoce como que tiene aplicabilidad industrial la materia objeto de reivindicaciones dirigidas al uso de un compuesto en el tratamiento medico, pero puede permitir, sin embargo, las reivindicaciones sobre un compuesto conocido para primer uso en tratamiento medico y el uso de un compuesto tal para la elaboración de un medicamento para un tratamiento medico nuevo.

13-08-04 17:11
2/08-2004 17:00 FAX +41 22 338 30

Frm-ZEALAND PHARMACEUTICALS A/S

+4545181375

T-380 S.03/03 F-087

UMPL/WIPO PIV
File copy

PCT/DK2003/000056


PATENT COOPERATION TREATY

PCT

NOTIFICATION OF THE RECORDING
OF A CHANGE(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

From the INTERNATIONAL BUREAU

To:

WYETH
Five Giralda Farms
Madison, NJ 07940
United States of AmericaDate of mailing (day/month/year)
18 July 2004 (18.07.2004)Applicant's or agent's file reference
016-2003 WOInternational application No.
PCT/DK2003/000056International filing date (day/month/year)
29 January 2003 (29.01.2003)

IMPORTANT NOTIFICATION

1. The following indications appeared on record concerning:

☒ the applicant ☐ the inventor ☐ the agent ☐ the common representative

Name and Address

ZEALAND PHARMA A/S
Smødeland 288
DK-2800 Glostrup
DenmarkState of Nationality
DKState of Residence
DKTelephone No.
+45 43 28 12 00Facsimile No.
+45 43 28 12 12

Teleprinter No.

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

☒ the person ☐ the name ☐ the address ☐ the nationality ☐ the residence

Name and Address

WYETH
Five Giralda Farms
Madison, NJ 07940
United States of AmericaState of Nationality
USState of Residence
US

Telephone No.

Facsimile No.

Teleprinter No.

3. Further observations, if necessary:

4. A copy of this notification has been sent to:

☒ the receiving Office ☐ the designated Offices concerned
☐ the International Searching Authority ☐ the elected Offices concerned
☒ the International Preliminary Examining Authority ☒ other: ZEALAND PHARMA A/SThe International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No. (41-22) 338.71.30

Authorized officer

Laurence FAHY (Fax 338-71-30)

Telephone No. (41-22) 338 9617

Form PCT/IB/308 (March 1994)

006357028